Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00

Bicara Therapeutics (NASDAQ:BCAX) had its price target upped by Wells Fargo & Company from $11.00 to $16.00 in a research note published on Tuesday,Benzinga reports. They currently have an equal weight rating on the stock.

Other research analysts also recently issued reports about the company. Bank of America started coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price for the company. Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday. Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $21.47 on Tuesday. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $21.50. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -8.49 and a beta of -1.23. The firm’s 50-day moving average is $17.36 and its 200-day moving average is $16.73.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. Sell-side analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In other news, CEO Claire Mazumdar sold 36,766 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $19.17, for a total transaction of $704,804.22. Following the transaction, the chief executive officer owned 339,392 shares in the company, valued at approximately $6,506,144.64. This trade represents a 9.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Raben sold 16,300 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the transaction, the insider owned 55,286 shares in the company, valued at approximately $1,023,896.72. This trade represents a 22.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 137,969 shares of company stock worth $2,586,198 over the last three months. Company insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BCAX. AQR Capital Management LLC acquired a new stake in shares of Bicara Therapeutics during the first quarter worth $248,000. Woodline Partners LP grew its stake in shares of Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after acquiring an additional 72,998 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after acquiring an additional 180,833 shares in the last quarter. Intech Investment Management LLC increased its position in Bicara Therapeutics by 65.3% during the second quarter. Intech Investment Management LLC now owns 27,673 shares of the company’s stock worth $257,000 after acquiring an additional 10,927 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Bicara Therapeutics by 26.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after purchasing an additional 5,664 shares in the last quarter.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 quarterly and full‑year EPS forecasts (Q1–Q4 and FY2026) and reiterated a “Buy” rating with a $42 price target — the firm trimmed expected losses for each quarter and the year, signaling improved analyst confidence. Read More.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on BCAX, adding third‑party validation from another biopharma‑focused shop that can boost investor sentiment. Read More.
• Positive Sentiment: Goldman Sachs published bullish commentary indicating expected upside for BCAX, which helps drive demand from institutional and retail investors watching analyst cues. Read More.
• Positive Sentiment: Wells Fargo highlighted strong price‑appreciation potential for Bicara, contributing additional buy‑side momentum. Read More.
• Positive Sentiment: Aggregate Wall Street price targets (per Zacks) imply roughly ~55% upside from current levels — the headline can attract momentum traders and investors seeking high‑growth biotechs. Read More.
• Neutral Sentiment: Recent Q4 2025 results showed a slight beat to loss estimates (EPS better than consensus by $0.04), but the company remains unprofitable with consensus FY2026 EPS still a negative figure — investors are reacting to rate of improvement, not profitability yet. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.